NCT01692184View on ClinicalTrials.gov

Safety and Pharmacokinetics of AVL-292 Following Multiple Doses and the Effect of Food on the Single-dose Pharmacokinetics of AVL-292

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

August 1, 2012

Primary Completion Date

October 8, 2012

Study Completion Date

October 8, 2012

Conditions
Healthy
Interventions
DRUG

50 mg AVL-292

DRUG

100 mg AVL-292

DRUG

200 mg AVL-292

DRUG

350 mg AVL-292

DRUG

Placebo capsules

Trial Locations (1)

75247

Covance Clinical Research Unit, Dallas

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
lead

Celgene

INDUSTRY